Compare EZGO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | LSTA |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.9M |
| IPO Year | 2020 | 2000 |
| Metric | EZGO | LSTA |
|---|---|---|
| Price | $1.60 | $3.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 83.1M | 31.8K |
| Earning Date | 07-01-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.01 | $1.81 |
| 52 Week High | $2.99 | $5.07 |
| Indicator | EZGO | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 40.29 |
| Support Level | $0.12 | $3.02 |
| Resistance Level | $2.22 | $3.41 |
| Average True Range (ATR) | 0.43 | 0.12 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 54.32 | 46.64 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.